Gam-COVID-Vac (Sputnik V): a heterologous adenoviral vector-based COVID-19 vaccine

The Sputnik V COVID-19 vaccine (Gam-COVID-Vac) is an adenoviral vector-based against the SARS-CoV-2 virus developed by Gamaleya National Research Centre for Epidemiology and Microbiology in Moscow, Russia. It consists of two recombinant adenovirus vectors; type 26 (rAd26) 5 (rAd5), with a heterologous approach used to reduce risk immune responses vector component. Findings from published studies showed that Gam-COVID-Vac was relatively safe, mostly mild local systemic reactions reported. Both rAd26-S rAd5-S had be administered develop effective neutralising antibodies. No cross-reactive antibodies viral component identified. phase 3 trial performed Russia only demonstrated efficacy 91.6% preventing disease. Common adverse events were flu-like symptoms, injection site reactions, headaches asthenia, which majority mild. Results ongoing using Belarus, United Arab Emirates India would useful demonstrate generalisability other population groups. Details safety surveillance data are awaited before submission regulatory approval. Keywords: Adenovirus Vaccines, COVID-19, Russia, vaccines